NCT05554406 – MM1YA-S01, “A Randomized Phase II Study Comparing Cytarabine + Daunorubicin(7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin +Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome+ Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk(Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; AMyeloMATCH Clinical Trial”
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. “High-risk” refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.